


May 11, 2023

ORCHPHARMA


524372

Subject Investors Presentation Q4 FY23 – Orchid Pharma Limited (“the Company”)

Orchid Pharma Limited

MARINA PETER  Digitally signed by
MARINA PETER
Date: 2023.05.11
13:26:05 +05'30'

Marina Peter
Company Secretary & Compliance Officer
Encl. as above



Annual Results


FY23

This presentation and the accompanying slides (the “Presentation”), which have been prepared by **Orchid Pharma Ltd** (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.


This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of


TOTAL INCOME




EBITDA




PAT




EXPENSES BREAKUP



LEVERAGE



LONG TERM DEBT FROM BANK



SUMMARY RESULTS

	Rs. In cr	
Particulars	Year 22-23	Year 21-22
Net Sales / Income from operations	666	557
Other Income	19	9
Total income	685	566
	-	-
Raw material cost	385	314
Employee benefit expenses	65	60
Finance costs	32	32
Depreciation and amortization expense	55	87
Other expenses	132	125
Total expenses	669	619
	-	-
Profit /(Loss) before exceptional items	16	-53

Thank You!